The present invention relates to novel crystalline forms of the plateletaggregation inhibitor(+)-(S)-methyl-2-(2-chlorophenyl)-6,7-dihydro-4H-thieno[3,2-c]pyrid-5-yl)acetate, clopidogrel (1), in the formof hydrogen bromide salts, identified as polymorph forms 1, 2 and 3. Thepresent invention furtherrelates to processes for preparing such forms, pharmaceutical compositionscomprising such forms,and uses for such forms and compositions. The pharmaceutical compositions maybe used, inparticular, for inhibiting platelet aggregation or for treating, preventing ormanaging thrombosis,atherothrombosis, an atherothrombotic event, ischaemic stroke, myocardialinfarction, non-Q-wavemyocardial infarction, atherosclerosis, peripheral arterial disease, orunstable angina. The presentinvention also relates to methods of treating said disorders.(see formula 1)
展开▼
